Sidera Bio

Sidera Bio is a pre-clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics that target RNA. Founded in 2023 by Dr. Jennifer Petter, a pioneer in the field and the former founder of Arrakis Therapeutics, the company aims to treat diseases by modulating RNA function directly. Sidera Bio utilizes a proprietary platform to identify small molecules that bind to specific RNA structures, offering a way to reach targets that are currently undruggable by protein-focused therapies. The company's research is primarily directed toward oncology, neurology, and rare genetic diseases. Based in Cambridge, Massachusetts, Sidera Bio is an Atlas Venture-backed company currently advancing its early-stage pipeline.